We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Diurnal Group plc (DNL) Ordinary 5p

Sell:12.25p Buy:12.50p 0 Change: No change
Market closed Prices as at close on 25 May 2022 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:12.25p
Buy:12.50p
Change: No change
Market closed Prices as at close on 25 May 2022 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:12.25p
Buy:12.50p
Change: No change
Market closed Prices as at close on 25 May 2022 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Diurnal Group plc is a United Kingdom-based specialty pharmaceutical company. The Company is focused on developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism. Its research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena. The Company's product, Alkindi, is a hydrocortisone specifically designed for use in children suffering from pediatric adrenal insufficiency (AI). Alkindi is an oral, immediate-release pediatric formulation of hydrocortisone granules in capsules for opening that allows for accurate age-appropriate dosing in children. Its pipeline includes Chronocort, DITEST, T3 modified release and Oligonucleotide (siRNA). Chronocort is a modified-release preparation of hydrocortisone that is specifically designed to mimic the circadian rhythm of cortisol.

Contact details

Address:
Heath Park
CARDIFF
CF14 4UJ
United Kingdom
Telephone:
+44 (029) 20682069
Website:
www.diurnal.co.uk/

Important dates

Future events
There are no future events available.
Past events
Interim results 22 March 2022 22/03/22
Trading Announcement 26 January 2022 26/01/22
AGM 19 November 2021 19/11/21
Annual report 06 October 2021 06/10/21
Final results 14 September 2021 14/09/21
Trading Announcement 28 July 2021 28/07/21

General stock information

EPIC:
DNL
ISIN:
GB00BDB6Q760
Market cap:
£21.00 million
Shares in issue:
169.72 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Richard Bungay
    Interim Chief Executive Officer, Chief Financial Officer, Company Secretary
  • Richard Ross
    Chief Scientific Officer, Executive Director
  • David Bevan
    Chief Business Officer
  • Stewart Jones
    Operations Director
  • John Porter
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.